P63、P53基因在卵巢癌中的表达及其在卡铂诱导卵巢癌细胞凋亡中的变化
|
摘要
目的：(1)探讨P63、P53基因在卵巢癌组织及SKOV3细胞株中的表达状况及该基因表达与卵巢癌临床特征间的关系。(2)探讨卡铂诱导人卵巢癌细胞株SKOV3凋亡后P63、P53基因的变化，初步探讨两者的相关性。方法：本研究采用(1)免疫组织化学方法研究P63、P53基因在9例正常卵巢，浆液性腺瘤40例，18例卵巢交界性肿瘤，卵巢浆液性腺癌48例石蜡组织中的蛋白表达。(2)用免疫组化法、流式细胞技术、REAL-TIME荧光定量RT-PCR方法研究卡铂诱导人卵巢癌细胞株SKOV3凋亡后P63、P53蛋白和mRNA的变化
结果：(1)正常卵巢组织中无P63、P53蛋白的表达。(2)卵巢浆液性腺瘤中无P63、P53蛋白的表达。(3)P63、P53蛋白定位在肿瘤细胞的胞核中。卵巢交界性肿瘤中P63、P53蛋白表达的阳性率分别为11.11％，16.7％。(3)卵巢浆液性腺癌中P53、P63表达阳性率分别为37.5％，31.25％明显高于交界性肿瘤和浆液性腺瘤组(P＜0.05)(4)P53蛋白表达与本病临床分期呈正相关(P＞0.05)，与血CA125测定值、腹水量以及腹水／腹腔冲洗液细胞学间无明显相关关系。(P＞0.05)。(5)P63基因与本病临床分期、组织学分级及呈正相关(6)卡铂能明显抑制SKOV3细胞的生长、其作用时间与细胞生长抑制率呈明显正相关，低浓度卡铂(10μg／ml)
Objectives:(1)To investigate the possible relationship between expression of P63, p53 and clinical charactersof ovarian carcinoma. (2) To study the variable at mRNA leve in apoptosis induced by caboplatin, and the possibility of P63 involving chemoresistanceof caboplatin and the primary relationship between P53and P63.
Methods: (1) p63, p53 expression were studied in 9 cases of normal ovarians, 40casesof serous cystadenoma, 18cases of ovarian bordline tumors, 48cases of serous cystadenocarcinoma by means of immunohistochemistry. (2) The apopotosis was induced by caboplatin, the protein and mRNA of P53, p63 were investigated by meanses of immunohistochemistry, flow cytometry and real-time fluorescence quantitative reverse transcription-PCR. Results: (1) No p53, P63protein was expressed in normal ovaries and.no expression in serous cystadenoma. (2) P53、 P63protein was found in nuclear . P53, p63 presented in16.7%, 11.11%of cases of
结果：(1)正常卵巢组织中无P63、P53蛋白的表达。(2)卵巢浆液性腺瘤中无P63、P53蛋白的表达。(3)P63、P53蛋白定位在肿瘤细胞的胞核中。卵巢交界性肿瘤中P63、P53蛋白表达的阳性率分别为11.11％，16.7％。(3)卵巢浆液性腺癌中P53、P63表达阳性率分别为37.5％，31.25％明显高于交界性肿瘤和浆液性腺瘤组(P＜0.05)(4)P53蛋白表达与本病临床分期呈正相关(P＞0.05)，与血CA125测定值、腹水量以及腹水／腹腔冲洗液细胞学间无明显相关关系。(P＞0.05)。(5)P63基因与本病临床分期、组织学分级及呈正相关(6)卡铂能明显抑制SKOV3细胞的生长、其作用时间与细胞生长抑制率呈明显正相关，低浓度卡铂(10μg／ml)
Objectives:(1)To investigate the possible relationship between expression of P63, p53 and clinical charactersof ovarian carcinoma. (2) To study the variable at mRNA leve in apoptosis induced by caboplatin, and the possibility of P63 involving chemoresistanceof caboplatin and the primary relationship between P53and P63.
Methods: (1) p63, p53 expression were studied in 9 cases of normal ovarians, 40casesof serous cystadenoma, 18cases of ovarian bordline tumors, 48cases of serous cystadenocarcinoma by means of immunohistochemistry. (2) The apopotosis was induced by caboplatin, the protein and mRNA of P53, p63 were investigated by meanses of immunohistochemistry, flow cytometry and real-time fluorescence quantitative reverse transcription-PCR. Results: (1) No p53, P63protein was expressed in normal ovaries and.no expression in serous cystadenoma. (2) P53、 P63protein was found in nuclear . P53, p63 presented in16.7%, 11.11%of cases of
引文
1．李玉林、唐建武主编．病理学．第6版．北京：人民卫生出版社，2004年9月
2．乐杰、谢辛、丰有吉主编．妇产科学．第6版，北京．人民卫生出版社，2004年9月
3．陈乐真主编．妇产科诊断病理学．第1版，北京．人民军医出版社，2002年2月
4．黄守国综述，江森审校．恶性卵巢肿瘤化疗和基因表达关系的研究进展．国外医学妇产科学分册，2002，29(4)：195-197
5. WooR A, Mclure KG, Lees-Miller SP, et al. DNA dependent protein kinase acts upstream of p53 in response to DNA damage[J]. Nature 1998, 394(6 694):700-704.
6. Hermeking H, Lengauer C, Polyak K, et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression[J].Mol Cell, 1997, 1 (1):3-11.
7. Peng CY, Graves PR, Thoma RS, et al.Mitotic and G2 checkpoint control regulation of 14-3-3 protein binding by phos-phorylation of Cdc25conserine-216[J].Science, 1997, 277 (5331):1501-1505.
8. Pfeifer G P, Denissenko M F. Formation and repair of DNA lesions in the p53 gene relation to cancer mutations [J] Environmol Mutagen, 1998, 31(3):197-205.
9. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer[J] Nature, 1998, 393(682):229-234.
10. Grossman SR, Perez M, Kung A L, et al.p300/MDM2 complexes participate in MDM2-mediated p53 degradation[J]. Molcell, 1998, 2(4):405-415.
11. Zhang Y, Xiong Y, Yarbrough W G, et al. ARF promotes MDM2 degradation and stabilizes p53:ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways [J].Cell, 1998, 92 (6):725-732.
12．徐海耿，王华．P53基因在上皮性卵巢癌的表达及临床意义．中国临床医学．2006，6(12)3：489-490
13．温凯辉，温砾，辛晓燕，卢小娟，李青．p53过表达、nm23低表达与卵巢癌浸润、转移关系的探讨．J Diag Pathol, December 2005, Vol.12，No．6．：176
14. Gomes CP, Andrade LA. PTEN and p53 expression in primary ovarian carcinomas: immunohistochemical study and discussion of pathogenetic mechanisms. International Journal of Gynecological Cancer. 16 Suppl 1:254-8, 2006 Jan-Feb.
16．邬东平，陈惠祯，龚玲玲．卵巢癌p53蛋白表达与细胞增殖状态及预后的关系．肿瘤防治研究2003年第30卷第4期
17. Zeime AG, Merth C. Why did P53 gene therapy fail in ovarian cancer. Lancet Oncology.2003 Jul, 4(7):415-22
18. Lee JS. Choi YD. Lee JH.et al.Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression.International Journal of Gynecological Cancer. 16 Suppl 1:247-53, 2006 Jan-Feb.
19. Zhao XD. Zhang Y. He SR. Yang L. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma]. [Chinese] Aizheng. 24(12):1542-5, 2005 Dec.
20. Kahlenberg MS, Stoler DL, Basik M, et al. p53 tumor suppressor gene status and the degree of genomic instability in sporadic colorectal cancers. J Natl Cancer Inst, 1996, 88:1665-1670.
21．姚桂梅，康志海．p53肿瘤抑制基因与卵巢癌(综述)．国外医学：遗传学分册，1998，18：152-155．
22. Moll UM, Esster S, Zaika A.P53, P63and P73-solos, alliances and feuds among family members.Biochimica et Biophysica Acta, 2001 Dec 28, 1552(2):47-59
23. Kylarova D, Vrchovecky J, Holinka M.Erdosova B.The occurrence of c-myc, p53 and Bcl-2 family proteins in the early phase of development of duodenal epithelium. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2004 Dec ;148(2):229-32
24. Maria C, Naria A, William G.p63 and p73:old members of a new family. Biochimica et B iophysica Acta.2000 mar:93-100
25. Rohlke P, Milde-Langosch k, Weyland C, et al. P53 is a persietent and prective marker in advanced ovarian carcinomas:Multivariate analysis including comparison with Ki67 immunoreactivity.J Cancer Res Clin oncol, 1997, 123(9):496-501
26. Sood AK, Sorosky JI, Dolan M, et al.P53 is a persietent and prective marker in advanced ovarian carcinomas:Multivariate analysis including comparison with Ki67 immunoreactivity. J Cancer Res Clin oncol, 1997, 123(9):496-501
27. Kanmura T, Sakai K, Kaku T, et al.. Comparison of p53 and CD44variant 6 expression between paired primary and recurrent ovarian cancer:An immunohistochemical analysis. Oncol Rep, 1999, 6(1):97-101
28. Kim J, Hwang ES, Kim JS, et al.Intraperiton tumor suppressor gene for ovarian cancer model in nude mouse.Cancer Gene Ther.1999, 6(2): 172-178
29. Kanmura T, Sakai K, Kaku T, et al..Comparison of p53 and CD44variant 6 expression between paired primary and recurrent ovarian cancer: An immunohistochemical analysis. Oncol Rep, 1999, 6(1):97-101
30. Kim J, Hwang ES, Kim JS, et al.Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse.Cancer Gene Ther.1999, 6(2):172-178
31. Schneider J, Pollan M, Jimenez E, etal.Nm23-H1 expression defines a high risk subpopulation of patients with early-stage epithelial ovarian carcinoma, Br Cancer, 2000, 82(10):1662-1667.
32. Lohrum MA, Vousden KH.Regulation and function of the p53-related proteins: same family, different rules. [Review] [60 refs] [Journal Article. Review. Review, Tutorial] Trends in Cell Biology. 10(5): 197-202, 2000 May
33. Park BJ, Lee S J, Kim J I, et al. Frequent alteration of p63 expression in human primary bladder carcinomas[J]. Cancer Res, 2000, 60(13): 3370.
34. Sunahara M, Shishikura T, Takahashi M, et al. Mutational analysis of p51A/TAp63gamma, a p53 homolog, in non small cell lung cancer and breast cancer [J]. Oncogene ,1999 ,18 (25) :3761.
35. Hibi K, Trink B , Patturajan M , et al. AIS is an oncogene amplified in squamous cell carcinoma[J] . Proc Natl Acad Sci USA , 2000,97(10) :5462.
36. Mai M , Huang H , Reed C , et al. Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions [J].Genomics ,1998,51(3) :359.
37. J Fontanini G, Faviana P, Luechi M, el al. A high vascular count and over, expression of vascular endothelial growth factor associated with unfavonrable prognesis in operated small cell lung carcinoma [J]. RrJ Cancer, 2002. 86(4): 558-563.
38. Yang A , Kaghad M , Wang Y, et al. p63 , a p53 homolog at 3q27-29 ,encodesmultipleproductswithtransactivating,death-inducing, and dominant-negative activities [J]. Mol Cell, 1998 ,2(3) :305.
39. Sniezek JC, Matheny KE, Westfall MD, Pietenpol JA.Dominant negative p63 isoform expression in head and neck squamous cell carcinoma, Laryngoscope. 2004 Dec;114(12):2063-72
40. Bortoluzzi MC, Yurgel LS, Dekker NP, Jordan RC, Regezi JA.Assessment of p63 expression in oral squamous cell carcinomas and dysplasias.Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Dec;98(6):698-704.
41. Sniezek JC, Matheny KE, Westfall MD, Pietenpol JA Dominant negative p63 isoform expression in head and neck squamous cell carcinoma.Laryngoscope. 2004 Dec;114(12):2063-72
42. Chovanec M, Smetana K Jr, Betka J,et al.Correlation of expression of nuclear proteins pKi67 and p63 with lectin histochemical features in head and neck squamous cell cancer. Int J Oncol. 2005 Aug ;27(2):409-15.
43. LoMuzio L, Santarelli A, Caltabiano R, et al.p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma.Hum Pathol. 2005 Feb ;36(2):187-94.
44. Au NH, Gown AM, Cheang M, Huntsman D, Yorida E, Elliott WM, Flint J, English J, Gilks CB, Grimes HL. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol. 2004 Sep ;12(3):240-7.
45. Emanuel P, Wang B, Wu M, Burstein DE. p63 Immunohistochemistry in the distinction of adenoid cystic carcinoma from basaloid squamous cell carcinoma. Mod Pathol, 2005 May ;18(5):645-50.
46. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005 Jul 13 ;:1-7
47．连利娟主编．林巧稚妇科肿瘤学．第3版，北京：人民卫生出版社．2001年6月
48. Poli Neto OB.Candido Dos Reis FJ. Zambelli Ramalho LN.et al.p63 expression in epithelial ovarian tumors. International Journal of Gynecological Cancer.16(1):152-5, 2006 Jan-Feb.
49. Levrero M, De Laurenzi C, Costanzo A.Structure, Function and regulation of P63and P73 Cell Death & Differentiation. 1999 Dec, 6(12): 1146-53
50．Steven A．Rosenberg主编，陈复兴，曹志章，徐开林译．Princjples and Practice of the Biologic Therapy of Cancer．北京：人民军医出版社．2005年6月
51．沈羽非，万福德主编．真核基因表达调控．北京：高等教育出版社．1997年12月
52．本杰明，卢因编著，余龙江，松敏，赵寿元主译．基因Ⅷ．北京：科学出版社．2005年2月
53．周俊宜编著．分子生物学基本技能和策略．(21世纪高等院校教材)北京：科学出版社．2003年8月
54．张维铭主编．现代分子生物学实验手册．北京：科学出版社．2003年
55．曹亚主编，李官成副主编．实用分子生物学操作指南．北京：人民卫生出版社．2003年10月
56．刘进元等编著．分子生物学实验指导．北京：清华大学出版社．2002年
57．叶林柏，郜金荣编著．基础分子生物学．科学出版社．北京．2000年8月
58. Blumenthal RD, Leone E, Goldenberg. DM. Tumor-specific dose scheduling of bimodal radioimmunotherapy and chemotherapy. Anticancer Res, 2003, 23:4613-4619.
59．司徒镇强，吴军正主编．细胞培养，第一版，西安：世界图书出版社，2004年3月
60．卢红梅，强亦忠，施勤，等．p53基因状态对人卵巢癌细胞辐射敏感性的影响，辐射防护，2001，Vol．21(6)：205
61. Liu JR, Opipari AW, Tan L, et al.Dysfunctional apoptosome activation In ovarian cancer:implications for chemoresistance.Cancer Res, 2002.62:924-931
62．栾英姿，李力，黎丹戎，等．五种卵巢癌耐药细胞系的建立及其部分耐药相关基因的表达，中华妇产产科杂志，2006年6月39卷第6期403-408
63. Satoh T , Nishida M, Tsunoda H , et al . Expression of glutathione S-transferase pi (GST-pi) in human malignant ovariantumors. Eur J Obstet Gynecol Reprod Biol,2001,96 :202-208
64. Hill BT, Moran E, Etievant C, et al. Low-dose twice-daily fractionated X-irradiation of ovarian tumor cells in vitro generates drug-resistant cells overexpressing two multidrug resistance-associated proteins , P-glycoprotein and MRP1. Anticancer Drugs ,2000,11:193-200.
65. Cvitkovic E. Ongoing and unsaid on oxaliplatin : the hope.Br J Cancer ,1998 ,77 Suppl 4 :8-ll.
66. Perego P , Giarola M, Righetti SC , et al. Association between Cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996 ,56 :5562562.
67. Asselin E , Mills GB , Tsang BK. XIAP regulates Akt activity and caspase3-dependent cleavage durincisplatin-inducedapoptosis in human ovarian epithelial cancer cells. Cancer Res , 2001,61:1862-1868
68. Cui W, Yazlovitskaya EM, Mayo MS , et al . Cisplatin-induced responseof c-un N-terminal kinase and extracellularsignalregulated protein kinases 1 and 2 in a series Of cisplatin-resistant ovarian carcinoma cell lines.Mol Carcinog ,2000, 29 :219-228.
69. Mercer WE. Checking on the cell cycle [J] . J Cell Biochem Suppl ,1998,30 (31) :50-54.
70. Schwartz D , Rotter V. p532dependent cell cycle control : response to genotoxic stress[In Process Citation] [J] . Cancer Biol ,1998 ,8 (5) :325-336.
71. Sanding BV ,Brand K,Herwig S , et al . p16 and p53 genes transferred with the help of adenovirus to induce apoptic tumor cell death[J]. Ug-eskr Laeger, 1997, 159(46):6825-6830.
72. Xie K, Wang Y, Huang S, et al. Nitric oxide-mediated apoptosis of K-1735 melanoma cells is associated with downregulation of Bc122 [J].Oncogene, 1997, 15 (7):1923-1930.
73. Musat M, Vax W, Borboli N, et al. Cell cycle dysregulation in pituitary oncogenesis.Front Horm Res. 2004 ;32:34-62.
74. Ng SW, Yiu GK, Liu Y, et al.Analysis of p73 in human borderline and invasive ovarian tumor.Oncogene. 2000 Apr 6 ;19(15):1885-90.
75. Djelloul S. Tarunina M. Barnouin K. et al.Differential protein expression, DNA binding and interaction with SV40 large tumour antigen implicate the p63-family of proteins in replicative senescence Oncogene. 21(7):981-9, 2002 Feb 7.
76. Hagiwara K. McMenamin MG. Miura K.et al. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers Cancer Research. 59(17):4165-9, 1999 Sep 1.
77. Chen X. The p53 family: same response, different signals?. [Review] [64 refs] Molecular Medicine Today. 5(9):387-92, 1999 Sep.
78. Yang A. Kaghad M. Wang Y. et al.63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities Molecular Cell. 2(3):305-16, 1998 Sep
79. Yang A, Schweitzer R, Sun D. et al. p63 is essential for regenerative proliferation in limb, eraniofacial and epithelical developmentlJ]. Nature, 1999. 398(6729): 714-718.
80. Gwosdz C, Balz V, Scheckenbach K, Bier H.p53, p63 and p73 expression in squamous cell carcinomas of the head and neck and their response to Cisplatin exposure.Adv Otorhinolaryngol. 2005;62:58-71
81. Avivi A, Ashur-Fabian O, Amariglio N,et al.p53--a key player in tumoral and evolutionary adaptation: a lesson from the Israeli blind subterranean mole rat.Cell Cyc le. 2005 Mar;4(3):368-72. Epub 2005 Mar 11
82. Laurora S, Tamagno E, Briatore F,et al.4-Hydroxynonenal modulation of p53 family gene expression in the SK-N-BE neuroblastoma cell line.Free Radic Biol Med. 2005 Jan 15;38(2):215-25
83. Yu JJ. Bicher A. Ma YK.et al.The Tumor Suppressor Protein p53 Functions Similarly to p63 and p73 in Activating Transcription In Vitro.Cancer Biol Ther. 2005 Apr;4(4):414-8. Epub 2005 Apr 21
84. Flores ER, Sengupta S, Miller JB,et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family.Cancer Cell. 2005 Apr;7(4):363-73
85. Koutsodontis G, V.Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis.Biochem J. 2005 Jul 15;389(Pt 2):443-55
86.Kong CZ,Zhu YY,Ma ZY,et al.Expression of lung resistance-related protein gene in transitional cell carcinoma of the bladder]Zhonghua Wai Ke Za Zhi. 2005 Jan 15;43(2):118-21. Chinese..
87.Irwin MS. Family feud in chemosensitvity: p73 and mutant p53. [Review] [61 refs] Cell Cycle. 3(3):319-23, 2004 Mar.
88.Gressner O, Schilling T, Lorenz K, et al. TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO Journal. 24(13):2458-71, 2005 Jul 6.
89. Hirotaka N, Makoto S, Katsura HN, et al. p53 homologue p63 represses epidermal growth factor receptor expression [J]. J Biol Chem, 2001, 276(45):41717.
90. Luan YZ, Li L, Li DR, et al. Establishment of 5 resistant ovarian cancer cell strains and expression of resistance-related genes]. Journal of Obstetrics & Gynecology]. 39(6):403-7, 2004 Jun.
91. Coleman AB, Metz MZ, Donohue CA, et al.Chemosensitization by fibroblast growth factor-2 is not dependent upon proliferation, S-phase accumulation, or p53 status.BiochemicalPharmacology.64(7):1111-23, 2002 Oct 1.
1. Zeimet AG Marth C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncology. 2003 ,Jul. 4(7):415-22
2. Marzars GR ,Jeanteur P ,Lynch H T,et al. Nucleotide sequence polymorphism in a hotspot mutation region of the p53 gene[J] . Oncogene ,1992,7(4) :781 - 782.
3. Soussi TC ,de Fromental C, May P. Structural aspects of the p53 protein in relation to gene evlution[J]. Oncogene ,1990,5 :945 - 952.
4. Lamb P ,Crawford L. Characterization of the human p53 gene[J] . Mol Cell Biol ,1986 , 6 :1379 -1383.
5. Wamakulassuriya KA S S , Johson N N. Expression of p53 mutant nuclear phosphoprotein in oral carcinoma and potentially malignant oral lesions[J]. J Oral Pathol Med ,1992,21 :404 - 410.
6. Milner J ,Medcalf A. Co - translation of activated mutant p53 with wild type drives the wild type p53 protein into the mutant conformation[J] . Cell ,1991,65(5) :765 - 774.
7.Chen P L , Chen Y,Book stein R ,et al. Genetic mechanisms of tumor suppression by the human p53 gene[J]. Science ,1990,250 :1575 -1580.
8 . Holl stein M,Sidransky D ,Wagelstein B ,et al. p53 mutation in human cancer[J]. Science ,1991,253:49 - 55.
9. Cheng J ,Haas M. Frequent mutations in the p53 tumor suppressor gene in human Leukemia T- cell lines[J] . Mol Cell Biol ,1990 ,10(1) :5502 -5509.
10. Braithwaite A W,Sturzbecher H W,Addison C ,et al. Mouse p53 inhibits Sv40 origin-dependent DNA replication [J] . Nature ,1997 ,329(6137) :458 -460.
11. Raycroft L, Wu H, Lozano G. Transcriptional activation by wild-type but not transforming mutant of the p53 anti -oncogene[J] Science, 1997, 249:1049-1051.
12. Wang E H, Friedman D N, Privets C. The murine p53 protein blocks replication of SV40 in vitro by inhibiting the initiation functions of SV40 large T antigene[J]. Cell, 1989, 57:379-392.
13. Kern S E, Kinzler KW, Baker SJ, et al. Mutant p53 proteins bind DNA abnormally in vitro[J]. Oncogene, 1991, 6:131-136.
14. Kikuchi-Yanshita R, Konishi M, Fukunari H, et al. Loss of expression of the DCC gene during progression of colorectal carcinomas in familial adenomatous polyposis and non-familial adenomatous [J]. Cancer Res, 1992, 52(12):3801-3803.
15. Gannon J V, Lane D P. p53 and DNA polymerase a completed for binding to SV40Tantigen[J] Ntaure 1987 ;329:456-458.
16. Hunter T York JD. Signal transduction. Unexpected mediators of protein phosphorylation.[comment], Science. 2004 Dec 17 ;306(5704):2101-5 ;
17. Mercer WE. Checking on the cell cycle. [Review] [25 refs] Journal of Cellular Biochemistry-Supplement. 1998. 30-31:50-4,
18. Schwartz D. Rotter V. p53-dependent cell cycle control: response to genotoxic stress. [Review] [172 refs] Seminars in Cancer Biology. 1998. 8(5):325-36,
19. Sandig BV. Brand K. Herwig S. Lukas J. Bartek J. Strauss M. [p16 and p53 genes transferred with the help of adenovirus to induce apoptic tumor cell death]. [Danish] Ugeskrifl for Laeger. 1997 Nov 10. 159(46):6825-30
20. Buckbinder L. Velasco-Miguel S. Chen Y. Xu N. Talbott R. Gelbert L. Gao J. Seizinger BR. Gutkind JS. Kley N. The p53 tumor suppressor targets a novel regulator of G protein signaling.Proceedings of the National Academy of Sciences of the United States of America. 1997 Jul 94(15):7868-72
21. Wang Y. Blandino G. Oren M. Givol D. Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs.Oncogene. 1998 Oct 15. 17(15):1923-30
22. Lonardo F. Ueda T. Huvos AG. Healey J. Ladanyi M. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Cancer. 79(8):1541-7, 1997 Apr 15.
23. Ling-Ling, Hsieh ;Jen-Tsung, Hsieh ;LI-Yu, Wang ;Chiung-Yau, Fang ;Shan-Hong, Chang ;Tse-Ching, Chen.P53 mutations in gastric cancer from Taiwan.Cancer Letters.volume:100, Issue:1-2, February 27, 1996 ; 107-113
24. Wang, Jaw-Yuan: Hsieh, Jan- en-Lu ;Chen, Fang-Ming ;et al.Alterations of APC, c-met, and P53genes in tumor tissue and serum of patients with gastric cancers.Journal of Surgical Research.Volume:120, Issue:2, August, 2004, pp.242-248
25. Mineta H. Miura K. Ogino T. Takebayashi S. Misawa K. Ueda Y. Vascular endothelial growth factor (VEGF) expression correlates withp53 and ki-67 expressions in tongue squamous cell carcinoma. Anticancer Research.22(2B): 2002 Mar-Apr. 1039-44,
26. wabuchi S. Muramatsu H. Chiba N. Kinio Y. Murakami Y. Sakaguchi T. Yokoyama K. Tamiya E. Simultaneous detection of near-field topographic and fluorescence images of human chromosomes via scanningnear-fieldoptical/atomic-force microscopy (SNOAM). Nucleic Acids Research.,1997 Apr 15. 25(8): 1662-3,
27. Nakai H. Misawa S. Toguchida J. Yandell DW. Ishizaki K. Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. Cancer Research. 52(23):6588-93,1992 Dec 1.
28. Wagata T,Shibagaki I , Imamurna M,et al. Loss of 17p ,mutation of the p53 gene , and overexpression of protein in esphageal seqamous cell carcinomas[J]. Cancer Res ,1993 ,53 :846 - 850.
29. Green M R. When the products of oncogenes and antioncogenes meet [J]. Cell ,1989 ,56:1-5.
30. Wolf D ,Harris N , Rotter V. Reconstitution of p53 expression in a nonproducer Ab - MulV - transformed cell line by transinfection of a functional p53 gene[J]. Cell ,1984,38 :119 -126.
31. Seruca R ,David L ,Holm R ,et al. p53 mutations in gastric carcinomas[J]. Br J Cancer ,1992 ,65(5) :708 - 710.
32.Sprunck C ,Tsai Y C ,Huang D P ,et al. Absence of p53 gene mutation in primarynasopharyngealcarcinomas[J] .Cancer Res ,1992 ,52(16) :4787 -4790.
33 Saramath D ,Panchnal R G,Nair R ,et al. Oncogene amplification in squamous cell of the oral cavity[J] . Jpn J Cancer Res ,1989 ,80 :430 - 434.
34. Maestro R, Dolcett R, Gasparotto D, et al. High frequency of p53 gene alte human squamous cell carcinoma of the larynx[J]. Oncogene, 1992, 7:1157-1166.
35．周向东，沈寒放，谭骏．p53基因缺失和248位密码子点突变与肺癌发生和预后间关系的研究[J]．中国肿瘤临床997，24(6)：415-418．
36．余春艳，魏峰，顾群，等．外阴白斑和鳞癌细胞中p53蛋白的表达[J]．第四军医大学学报，2000，21(4)：462-463．
37. Yuan Y, Kim W H, Han H S, et al. Establishment and characterization of humanovarian carcinoma cell lines[J]. Gynecol Oncol, 1997, 66(3):378-387.
38. Rodrigues N R, Rowan A, Smith M E F, et al. p53 mutation in colorectal cancer [J]. Proc Natl Acad Sci USA, 1990, 87:7555-7559.
39. Luria D, Avgad S, Cohem I J, et al. p53 mutation as the second event in juvenile chronic myelogenous leukemia in a patient with neurofibromatosis type Ⅰ[J]. Cancer, 1997, 80(10):2013-2018.
40. Cherney B W, Bhatia K G, Sgadavi C, et al. Role of the p53 tumor suppressor gene in the tumorigenicity of Burkittps lymphoma cells[J]. Cancer Res, 1997, 57(12):2508-2515.
41．张晓东，王文亮，穆峰．肝癌细胞转染野生型p53基因稳定表达后肝癌细胞出现自发凋亡[J]．第四军医大学学报，1996，17(6)：469-470．
42．郭洪涛，刘彤华，高洁．人胰腺癌中MDM2癌基因的表达对野生型p53的拮抗作用[J]．中华病理学杂志，1996，25(4)：232-235．
43．张玉玲．腺病毒介导的野生型p53表达诱导前列腺癌细胞死亡并抑制肿瘤形成[J]．国外医学(分子生物学分册，1996，18(5)：239．
44．李东霞，涂平，马圣清．皮肤鳞状上皮细胞肿瘤p53蛋白的表达[J]．中华皮肤科杂志，1996，29(1)：41-42．
45. Nigro J M, Baker S J, Presinger A C, et al. Mutations in the p53 gene occur in diverse human types[J]. Nature, 1989, 342:705-708.
46. Shimada T. Current status and future prospects of human gene therapy. [Review] [27 refs] Acta Paediatrica Japonica. 1996 Apr. 38(2):176-81
47. Chen Xiaowei ; Cao Keli ; Liu Depei ; Wang Zhizhong ; Liang Chihchuan. Construction of the wt-p53 Gene Recombinant Retroviral Vector Inhibiting the Growth of Laryngocarcinoma Cell Line.ACTA ACADEMIAE MEDICINAE SINICAE.1996(4):179-181
47. Cascallo M. Capella G. Mazo A. Alemany R. Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Research. 2003 Sep 1. 63(17):5544-50
48. Blasco F. Penuelas S. Cascallo M. Hernandez JL. Alemany C. Masa M. Calbo J. Soler M. Nicolas M. Perez-Torras S. Gomez A. Tarrason G. Noe V. Mazo A. Ciudad CJ. Piulats J. Expression profiles of a human pancreatic cancer cell line upon induction of apoptosis search for modulators in cancer therapy. Oncology. 2004. 67(3-4):277-90
49. Chin KV. Alabanza L. Fujii K. Kudoh K. Kita T. Kikuchi Y Selvanayagam ZE. Wong YF. Lin Y. Shih WC. Application of expression genomics for predicting treatment response in cancer. Annals of the New York Academy of Sciences. 2005 Nov. 1058:186-95,
50. Thottassery JV. Westbrook L. Someya H. Parker WB. c-Abl-independent p73 stabilization during gemcitabine-4'-thio-beta-D-arabin of uranosy lcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells.Molecular Cancer Therapeutics. 2006 Feb. 5(2):400-10,
51. Li JH. Lax SA. Kim J. Klamut H. Liu FF. The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma. International Journal of Radiation Oncology, Biology, Physics. 1999 Feb 1. 43(3):607-16,
52. Popham HJ. Bischoff DS. Slavicek JM. Both Lymantria dispar nucleopolyhedrovirus enhancin genes contribute to viral potency. Journal of Virology. 2001 Sep. 75(18):8639-48,
53.Lee,Chien-Hsin;Ni,Yen-Hsuan;Chen,Chia-Chi;Chou,Chen-Kung;Chang,F u-Hsiung.Synergistic effect of polyethylenimine and cationic liposomes in nucleic acid delivery to human cancer cells.Biochimica et Biophysica Acta(BBA)/Biomembranes, Volume: 1611, Issue: 1-2, April 1, 2003, pp. 55-62
54.Skilling Jeffiey S; Squatrito, Robert C; Connor, Joseph P;, Niemann, Theodore; Buller Richard E p53 Gene Mutation Analysis and Antisense-Mediated Growth Inhibition of Human Ovarian Carcinoma Cell Lines Gynecologic Oncology Volume: 60, Issue: 1, January, 1996, pp. 72-80
55. Buller RE. Sood AK. Lallas T. Buekers T. Skilling JS. Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer.[see comment]. Journal of the National Cancer Institute. 1999 Feb 17. 91(4):339-46
56. Bishop MR. Iversen PL. Bayever E. Sharp JG. Greiner TC. Copple BL. Ruddon R. Zon G. Spinolo J. Arneson M. Armitage JO. Kessinger A. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. [see comment]. Journal of Clinical Oncology. 1996 Apr. 14(4): 1320-6
57 .Gomyo Y. Sasaki J. Branch C. Roth JA. Mukhopadhyay 5-aza-2'-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells. Oncogene. 2004 Sep. 23(40):6779-87,
58. Yanuck M. Carbone DP. Pendleton CD. Tsukui T. Winter SF. Minna JD. Berzofsky JA. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Research. 1993 Jul 53(14):3257-61
59. Ciernik IF. Berzofsky JA. Carbone DP. Human lung cancer cells endogenously expressing mutant p53 process and present the mutant epitope and are lysed by mutant-specific cytotoxic T lymphocytes.Clinical Cancer Research. 1996 May. 2(5):877-82,
60. Wilson JM. Gendicine: the first commercial gene therapy product. [Chinese, English] Human Gene Therapy. 16(9): 1014-5, 2005 Sep.
61. Patil SD. Rhodes DG. Burgess DJ. DNA-based therapeutics and DNA delivery systems: a comprehensive review. [Review] [159 refs] AAPS Journal., 2005. 7(1):E61-77
62. Kaghad M,Bonner H, Yang A,etal.Monoallelically expressed gene related to P53 at P63,a region frequently deleted in neuroblastoma and other human cancers[J].Cell. 1997,90(4):809.
63. Yang A,Kaghad M, Wang Y,et al.P63,a p53 homolog at 3q27-29,encodes multiple productswith transactivating,death-inducing, and dominant-negative activities[J].Mol cell.1998,2(3):305
64. Schmale H , Bamberger C. A novel protein with strong homology to the tumor suppressor p53 [J]. Oncogene , 1997 ,15 (11) :1363.
65. Osada M , Ohba M , Kawahara C , et al. Cloning and func2 tional analysis of human p51 , which structurally and func2tionally resembles p53[J]. Nat. Med , 1998 ,4(7) :839.
66. Trink B , Okami K, Wu L , et al. A new human p53 homo2 logue[J] . Nat. Med, 1998,4(7) :747.
67. Senoo M , Seki N, Ohira M , et al. A second p532related protein , p73L, with high homology to p73 [J] . Biochem Biophys Res Commun , 1998,248(3) :603.
68. Tan M , Bian J , Guan K, et al. p53CP is p51/ p63 , the third member of the p53 gene family : partial purification and characterization[J] . Carcinogenesis , 2001,22(2) :295.
69. Lee L , Walsh P , Prater C , et al. Characterization of an au2 toantigen associated with chronic ulcerative stomatitis : TheCUSP autoantigen is a member of the p53 family[J]. J In2 vest Dermatol, 1999,113(2) .146.
70. Zeng X, Zhu Y, Lu H. NBP is the p53 homolog p63[J] .Carcinogenesis, 2001,22(2) : 215.
71. Ratovitski EA , Patturajan M , Hibi K, et al. p53 associates with and targets Delta Np63 into a protein degradation vitski EA,Patturajan M,Hibi K,et al.P53 associates with and targets Delta Np63 into a protein degradation pathway[J].Proc Natl Acad Sci USA,2001,98(4):1817
72. Irwin MS, Kaelim WG. p53 familv update: p73 and p63develop their own identities[J]. Cell Growth Differ, 20012(7): 337—349.
73. Benard J, Douc-Rasy S, Ahomadegbe JC. TP53 family members and human cancers[J]. Hum Mutat. 2003, 21(3): 182-191
74.VogelsteinB,LaneD,LevineAJ.SurfingtheP53net-work.[J]Nature,2000.408 (6810):307
75. Yang A, Schweitzer R, Sun D. et al. p63 is essential for regenerative proliferation in limb , eraniofacial and epithelical development[J]. Nature, 1999. 398(6729): 714—718
76. Irwin MS, Kaelim WG. p53 family update: p73 and p63 develop their ownidentities[J]. Cell Growth Differ, 2004.12(7): 337—349.
77. Yang A , Kaghad M , Wang Y, et al. p63 , a p53 homolog at 3q27-29 , encodes multiple products with transactivating ,death-inducing , and dominant-negative activities [J]. Mol Cell, 1998,2(3) :305.
78. Schmale H , Bamberger C. A novel protein with strong homology to the tumor suppressor p53 [J]. Oncogene, 1997 ,15 (11) :1363.
79. Osada M , Ohba M , Kawahara C , et al. Cloning and functional analysis of human p51 , which structurally and functionally resembles p53[J] . Nat. Med, 1998 ,4(7) :839.
80. Trink B , Okami K, Wu L, et al. A new human p53 homologue[J]. Nat. Med, 1998 ,4(7) :747.
81. Senoo M , Seki N , Ohira M , et al. A second p53-related protein , p73L, with high homology to p73 [J] . Biochem Biophys Res Commun , 1998 ,248(3) :603.
82 .Parsa R , Yang A , McKeon F , et al. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes [J]. J Investig Dermatol, 1999 ,113 (6) :
83. Quade BJ , Yang A , Wang Y, et al. Expression of the p53 homologue p63 in early cervical neoplasia[J]. Gynecol. Oncol, 2001,80 (1) :24.
84. Senoo M , Matsumura Y, Habus S , et al. Tap63gamma(p51A) and dNp63aipha (p73L), two major isoforms of the p63 gene , exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression [J]. Oncogene ,2002,21 (16) :2455.
85. Hirotaka N, Makoto S , Katsura HN , et al. p53 homologue p63 represses epidermal growth factor receptor expression [J]. J Biol Chem, 2001,276(45) :41717.
86. Vincek V,Knowles N,Ii J.et al.Expression of P63mRNA isoforms in normal human tissue(J).Anticancer Res,2003.23(5A):3945-3948.
87. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes muhipie products with transactivatin death·inducing, and dominant negative activities [J]. Mol Cell,1998,2(3):305
88. Tsujita-kyutoku M,Kiuchi K,Danbara N,et al.P63 espression in normal human epidermjis and epidermal appendageas and their tumors(J).Jeutan Pathol,2003,30(1):11-17
89. Van Bokhoven H ,Brunner HG. Splitting p63 [J] . Am J Hum Genet ,2002,71 (1) :1213.
90. Westfall MD ,Pietenpol J p63 :Molecular complexity in development and cancer[J]Carcinogenesis ,2004,25(6) :8572864.
91. Strano E ,Munarriz H. Physical interaction with Yes - associated pro2 tein enhances p73 transcriptional activity [J]. Biol Chem,2001,276 : 15164 -15173.
92 .Chi SW,Ayed A. Solution structure of a conserved C - terminal domin of p73 with structural homology to the SAM domain[J]. EMBO ,1999 , 18 :4438 - 4445.. Carcinogenesis ,2004 ,25(6) :8572864.
93. Mills AA , Zheng B , Wang XJ , et al. p63 is a p53 homologue required for limb and epidermal morphogenesis [J] .Nature , 1999,398(6729): 708.
94. Yang A , Schweitzer R , Sun D , et al. p63 is essential for regenerativproliferatio in limb , craniofacial and epithelial development [J]. Nature , 1999 ,398(6729) :714.
95. Celli J , Duijf P , Hamel BCJ , et al. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome[J] . Cell , 1999,99(2): 143.
96. Ianakiev P , Kilpatrick MW , Toudiarsk I ,et al Split-hand/split-foodmal formation is caused by mutations in the p63 gene on 3q27[J] Am J Hum Genet ,2000 ,67(1) :59.
97. McGrath JA , Duijf PH , Doetsch V , et al. Hay-Wells syndrome is caused by het2001,10 (3) :221.
98. Chompret A. The Li-Fraumeni syndrome [J] . Biochimie.erozygous missense mutations in the SAM domain of p63 [J] . Hum Mol Genet, ,2002 84 (1) :75
99. Park BJ , Lee SJ , Kim J I, et al. Frequent alteration of p63 expression in human primary bladder carcinomas[J]. Cancer Res , 2000,60(13) :3370.
100. Sunahara M , Shishikura T , Takahashi M , et al. Mutational analysis of p51A/ TAp63gamma , a p53 homolog , in non small cell lung cancer and breast cancer [J]. Oncogene ,1999 ,18 (25) :3761.
101. Hibi K, Trink B , Patturajan M , et al. AIS is an oncogene amplified in squamous cell carcinoma[J] . Proc Natl Acad Sci USA , 2000,97(10) :5462.
102. Liefer KM , Koster MI , Wang XJ , et al. Down-regulation of p63 is required for epidermal UV2B2induced apoptosis[J] .Cancer Res , 2000 ,60(15) :4016.
103. Mai M , Huang H , Reed C , et al. Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p2arm deletions [J].Genomics ,1998, 51(3) :359.
104. Marin MC , Kaelin W. p63 and p73 : old members of a new family[J] .Biochem BiophysActa, 2000,1470(3) :93.
105. Osada M,Ohba M,Kawabara C, et al. Cloning and functional analysis of human p51 ,which structurally and functionally resembles p53 [J]. Nat Med ,1998,4 (7) .839-843.
106. Di Como CJ ,Urist MJ ,Babayan I , et al . p63 expression profiles in human normal and tumor tissues[J] . Clin Cancer Res ,2002 ,8 (2) :494-501.
107. Reis-Filho JS ,Simpson PT ,Martins A , et al . Distributionofp63 ,cytokeratins 5/ 6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP24 multi-tumor tissue microarray [J]. Virchows Arch ,2003 ,443(2) :122-132.
108. Massion PP ,Taflan PM,Jamshedur Rahman SM, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis[J]. Cancer Res ,2003 ,63(21) :7113-7121.
109. Chen YK,Huse SS ,Lin LM, et al. Differential expression of p53 ,p63 and p73 proteins in human buccal squamous2cell carcinomas[J]. Clin Otolaryngol ,2003 ,28(5) :451-455.
110. Qureshi HS ,Ormsby AH ,Lee MW, et al. The diagnostic utility of p63 , CK5/ 6 ,CK7 ,and CK 20 in distinguishing primary cutaneous adnexal neoplasms from metastatic carcinomas [J] . J Cutan Pathol , 2004 , 31(2):145-152.
111. Park BJ ,Lee SJ ,KimJ I, et al. Frequent alteration of p63 expression in human primary bladder carcinomas [J] . Cancer Res ,2000 , 60 (13) :3370-3374.
112. Langner C, Ratschek M, Tsybrovskyy O, et al. p63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal cell carcinoma even in poorly differentiated tumors [J] .Histochem Cytochem,2003 ,51(8): 1097-1099.
113. Reis-Filho JS ,Milanezi F ,Amendoeira I, et al. Distribution of p63 ,a novel myoepithelial marker , in fine-needle aspiration biopsies of the breast: an analysis of 82 samples[J]. Cancer ,2003 ,99 (3) .172-179.
114. Stefanou D ,Batistatou A ,Nonni A, et al. p63 expression in benign and malignant breast lesions[J]. Histol Histopathol ,2004 ,19(2) :465-471.
115. Unger P ,Ewart M,Wang BY, et al . Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis : a pathobiologic link[J] ?Hum Pathol ,2003 ,34(8) .764-769.
116. Mai M , Huang H , Reed C , et al. Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions [J]. Genomics , 1998 , 51(3) :359.
117. Kaghad M , Bonnet H , Yang A , et al. Monoallelically expressed gene related to p53 at 1p36 , a region frequently deleted in neuroblastoma and other human cancers[J] . Cell. 1997 , 90 (4) :809.
118. Marin MC , Kaelin W. p63 and p73 : old members of a new family[J] .Biochem BiophysActa, 2000,1470(3) :93.
119. Arrowsmith CH. Structure and function in the p53 family [J] . Cell Death Differ, 1999 ,6(12) :1169.
120. Kaghad M, Bonnet H , Yang A , et all Monoallelically expressed gene-related to P53 at 1p36 , a region frequently deleted in neuroblastoma and other human cancer[J]1 Cell ,1997,90(4) :809 - 819
121. Chi SW, Ayed A , Arrowsmith CH1 Solution structure of a conserved C-terminaldomain of P73 withstructura lhomology to the SAM domain [J] EMBOJ ,1999 ,18(16) :4438 - 4445
122. Yang A , Kaghad M, Wang Y, et all P63 ,a P53 homolog at 3q27-29 ,encodes multiple products with transactivating death-inducing and dominant negative activities[J]MoI Cell ,1998,2 (3) :305 - 316
123. Nakagawa T , Takahashi M, Ozaki T , et all Autoinhibitory regulation of P63 byANP73 to modulate cell survival and death through a P732specific target element within theANP73 promoter[J]lMol Cell Biol ,2002 ,22(8) :2575 - 2585
124. Kartasheva N, Contente A, Lenz2St¨oppler C, et all P53 induces the expression P73AN , establishing an autoregulatory feedback loop [J]Oncogene , 2002 ,21(31): 4715 - 4727
125. Haupt Y, Maya R , Kazaz A , Oren M1MDM2 promotes the rapid degradation of P53[J],Nature ,1997 ,387 (6630) :296 - 299
126. Minty A, Dumont X, Kaghad M, et all Cvalent modification of P73a by SUMO211Two2hybrid screening with P73 identifies novel SUMO21 in-teracting proteins and a SUM021 interaction motif [J] 1J Boil Chem,2000,275 (46) :36316 - 36323
127. Calabro V , Mansueto G, Parisi T, et all The human MDM2 oncopro tein increases the transcriptional activity and the protein level of the P53-homologue P63[J]1J Biol Chem,2001,277(4) :2674 - 2681
128. Stiewe T, Theseling CC, Putzer BM1 Transactivation deficient Delta TaP73 inhibits P53 by direct competition for DNA binding implications for tumorigenesis[J]J Biol Chem,2002,277(16): 14177 -14185
129. Grob TJ , FeyMF, Tobler A1 The two faces of P73[J]1Cell Death Dif feer, 2002,9(3) :237-245
130. Irwin Ms, Kaelin WG1P53 family update : P73 and P63 develop their own identities[J]1 Cell Growth Differ ,2001,12(7) :337 - 349
131. Kaghad M, Bonnet H, Yang A, et all Monoallelically expressed gene related to P53 at 1p36 , a region frequently deleted in neuroblastoma and other human cancer[J]1 Cell ,1997,90(4) :809 - 819
132. Yang A , Kaghad M, Wang Y, et all P63 ,a P53 homolog at 3q27-29 ,encodes multiple products with transactivating death-inducing and dominant negative activities[J]Mol Cell ,1998,2 (3) :305 - 316
133. Ozaki T , Nala M, Takda N , et all Deletion of the COOH-terminal region of P73alpha enhances both its transactivation function and DNA binding activity but inhibits induction of apoptosis in mammalian cells [J] Cancer Res , 1999 , 59 (23): 5902 - 5907
134. Gong J , Costanzo A , Yang H , et all The tyrosine kinase c-Abl regulates P73 in apoptotic response to cisplatin-induced DNA damage [J]Nature, 1999, 399(6738): 806-808
135. Liefer KM, Koster MI, Wang XJ, et all Down-regulation of P63 is require for epidermal UVB-induced apoptosis [J] Cancer Res, 2000, 60(15):4016-4020
136. Flores ER, Tsai KY, Crowley D, et all P63 and P73 are required for P53-dependent apoptosis in response to DNA damage[J] Nature, 2002, 416(6880): 560-564
137. Strano S, Fontemaggi G, Costanzo A, et all Physical interaction with human tumor-derived P53 mutants inhibits P63 activities [J] JBiolChem, 2002, 277(21):8817-1882
138. Park JJ, Sun D, Quade BJ, et all Stratified mucin-producing intraepithelial lesions of the cervix: adenosquamous or columnar cell neoplasia[J]AmJ Surg Pathol, 2000, 24(10):1414-1419
139. Patturajan M, Nomoto S, Sommer M, et all ΔNP63 induces β-catenin nuclear accumulation and signaling [J] Cancer Cell, 2002, 1(4):369-379
140. Yang A, Schweitzer R, Sun D, et all P63 is essential forregenerativeproliferation in limb, craniofacial and epithelial development [J]Nature, 1999, 398 (6729):714-718
141. Celli J, Duijf P, Hamel BC, et all Heteozygous gremlin mutations in the P53 homolog P63 are the cause of EEC syndrome[J]1 Cell, 1999, 99(2):143-153
2．乐杰、谢辛、丰有吉主编．妇产科学．第6版，北京．人民卫生出版社，2004年9月
3．陈乐真主编．妇产科诊断病理学．第1版，北京．人民军医出版社，2002年2月
4．黄守国综述，江森审校．恶性卵巢肿瘤化疗和基因表达关系的研究进展．国外医学妇产科学分册，2002，29(4)：195-197
5. WooR A, Mclure KG, Lees-Miller SP, et al. DNA dependent protein kinase acts upstream of p53 in response to DNA damage[J]. Nature 1998, 394(6 694):700-704.
6. Hermeking H, Lengauer C, Polyak K, et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression[J].Mol Cell, 1997, 1 (1):3-11.
7. Peng CY, Graves PR, Thoma RS, et al.Mitotic and G2 checkpoint control regulation of 14-3-3 protein binding by phos-phorylation of Cdc25conserine-216[J].Science, 1997, 277 (5331):1501-1505.
8. Pfeifer G P, Denissenko M F. Formation and repair of DNA lesions in the p53 gene relation to cancer mutations [J] Environmol Mutagen, 1998, 31(3):197-205.
9. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer[J] Nature, 1998, 393(682):229-234.
10. Grossman SR, Perez M, Kung A L, et al.p300/MDM2 complexes participate in MDM2-mediated p53 degradation[J]. Molcell, 1998, 2(4):405-415.
11. Zhang Y, Xiong Y, Yarbrough W G, et al. ARF promotes MDM2 degradation and stabilizes p53:ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways [J].Cell, 1998, 92 (6):725-732.
12．徐海耿，王华．P53基因在上皮性卵巢癌的表达及临床意义．中国临床医学．2006，6(12)3：489-490
13．温凯辉，温砾，辛晓燕，卢小娟，李青．p53过表达、nm23低表达与卵巢癌浸润、转移关系的探讨．J Diag Pathol, December 2005, Vol.12，No．6．：176
14. Gomes CP, Andrade LA. PTEN and p53 expression in primary ovarian carcinomas: immunohistochemical study and discussion of pathogenetic mechanisms. International Journal of Gynecological Cancer. 16 Suppl 1:254-8, 2006 Jan-Feb.
16．邬东平，陈惠祯，龚玲玲．卵巢癌p53蛋白表达与细胞增殖状态及预后的关系．肿瘤防治研究2003年第30卷第4期
17. Zeime AG, Merth C. Why did P53 gene therapy fail in ovarian cancer. Lancet Oncology.2003 Jul, 4(7):415-22
18. Lee JS. Choi YD. Lee JH.et al.Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression.International Journal of Gynecological Cancer. 16 Suppl 1:247-53, 2006 Jan-Feb.
19. Zhao XD. Zhang Y. He SR. Yang L. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma]. [Chinese] Aizheng. 24(12):1542-5, 2005 Dec.
20. Kahlenberg MS, Stoler DL, Basik M, et al. p53 tumor suppressor gene status and the degree of genomic instability in sporadic colorectal cancers. J Natl Cancer Inst, 1996, 88:1665-1670.
21．姚桂梅，康志海．p53肿瘤抑制基因与卵巢癌(综述)．国外医学：遗传学分册，1998，18：152-155．
22. Moll UM, Esster S, Zaika A.P53, P63and P73-solos, alliances and feuds among family members.Biochimica et Biophysica Acta, 2001 Dec 28, 1552(2):47-59
23. Kylarova D, Vrchovecky J, Holinka M.Erdosova B.The occurrence of c-myc, p53 and Bcl-2 family proteins in the early phase of development of duodenal epithelium. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2004 Dec ;148(2):229-32
24. Maria C, Naria A, William G.p63 and p73:old members of a new family. Biochimica et B iophysica Acta.2000 mar:93-100
25. Rohlke P, Milde-Langosch k, Weyland C, et al. P53 is a persietent and prective marker in advanced ovarian carcinomas:Multivariate analysis including comparison with Ki67 immunoreactivity.J Cancer Res Clin oncol, 1997, 123(9):496-501
26. Sood AK, Sorosky JI, Dolan M, et al.P53 is a persietent and prective marker in advanced ovarian carcinomas:Multivariate analysis including comparison with Ki67 immunoreactivity. J Cancer Res Clin oncol, 1997, 123(9):496-501
27. Kanmura T, Sakai K, Kaku T, et al.. Comparison of p53 and CD44variant 6 expression between paired primary and recurrent ovarian cancer:An immunohistochemical analysis. Oncol Rep, 1999, 6(1):97-101
28. Kim J, Hwang ES, Kim JS, et al.Intraperiton tumor suppressor gene for ovarian cancer model in nude mouse.Cancer Gene Ther.1999, 6(2): 172-178
29. Kanmura T, Sakai K, Kaku T, et al..Comparison of p53 and CD44variant 6 expression between paired primary and recurrent ovarian cancer: An immunohistochemical analysis. Oncol Rep, 1999, 6(1):97-101
30. Kim J, Hwang ES, Kim JS, et al.Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse.Cancer Gene Ther.1999, 6(2):172-178
31. Schneider J, Pollan M, Jimenez E, etal.Nm23-H1 expression defines a high risk subpopulation of patients with early-stage epithelial ovarian carcinoma, Br Cancer, 2000, 82(10):1662-1667.
32. Lohrum MA, Vousden KH.Regulation and function of the p53-related proteins: same family, different rules. [Review] [60 refs] [Journal Article. Review. Review, Tutorial] Trends in Cell Biology. 10(5): 197-202, 2000 May
33. Park BJ, Lee S J, Kim J I, et al. Frequent alteration of p63 expression in human primary bladder carcinomas[J]. Cancer Res, 2000, 60(13): 3370.
34. Sunahara M, Shishikura T, Takahashi M, et al. Mutational analysis of p51A/TAp63gamma, a p53 homolog, in non small cell lung cancer and breast cancer [J]. Oncogene ,1999 ,18 (25) :3761.
35. Hibi K, Trink B , Patturajan M , et al. AIS is an oncogene amplified in squamous cell carcinoma[J] . Proc Natl Acad Sci USA , 2000,97(10) :5462.
36. Mai M , Huang H , Reed C , et al. Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions [J].Genomics ,1998,51(3) :359.
37. J Fontanini G, Faviana P, Luechi M, el al. A high vascular count and over, expression of vascular endothelial growth factor associated with unfavonrable prognesis in operated small cell lung carcinoma [J]. RrJ Cancer, 2002. 86(4): 558-563.
38. Yang A , Kaghad M , Wang Y, et al. p63 , a p53 homolog at 3q27-29 ,encodesmultipleproductswithtransactivating,death-inducing, and dominant-negative activities [J]. Mol Cell, 1998 ,2(3) :305.
39. Sniezek JC, Matheny KE, Westfall MD, Pietenpol JA.Dominant negative p63 isoform expression in head and neck squamous cell carcinoma, Laryngoscope. 2004 Dec;114(12):2063-72
40. Bortoluzzi MC, Yurgel LS, Dekker NP, Jordan RC, Regezi JA.Assessment of p63 expression in oral squamous cell carcinomas and dysplasias.Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Dec;98(6):698-704.
41. Sniezek JC, Matheny KE, Westfall MD, Pietenpol JA Dominant negative p63 isoform expression in head and neck squamous cell carcinoma.Laryngoscope. 2004 Dec;114(12):2063-72
42. Chovanec M, Smetana K Jr, Betka J,et al.Correlation of expression of nuclear proteins pKi67 and p63 with lectin histochemical features in head and neck squamous cell cancer. Int J Oncol. 2005 Aug ;27(2):409-15.
43. LoMuzio L, Santarelli A, Caltabiano R, et al.p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma.Hum Pathol. 2005 Feb ;36(2):187-94.
44. Au NH, Gown AM, Cheang M, Huntsman D, Yorida E, Elliott WM, Flint J, English J, Gilks CB, Grimes HL. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol. 2004 Sep ;12(3):240-7.
45. Emanuel P, Wang B, Wu M, Burstein DE. p63 Immunohistochemistry in the distinction of adenoid cystic carcinoma from basaloid squamous cell carcinoma. Mod Pathol, 2005 May ;18(5):645-50.
46. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005 Jul 13 ;:1-7
47．连利娟主编．林巧稚妇科肿瘤学．第3版，北京：人民卫生出版社．2001年6月
48. Poli Neto OB.Candido Dos Reis FJ. Zambelli Ramalho LN.et al.p63 expression in epithelial ovarian tumors. International Journal of Gynecological Cancer.16(1):152-5, 2006 Jan-Feb.
49. Levrero M, De Laurenzi C, Costanzo A.Structure, Function and regulation of P63and P73 Cell Death & Differentiation. 1999 Dec, 6(12): 1146-53
50．Steven A．Rosenberg主编，陈复兴，曹志章，徐开林译．Princjples and Practice of the Biologic Therapy of Cancer．北京：人民军医出版社．2005年6月
51．沈羽非，万福德主编．真核基因表达调控．北京：高等教育出版社．1997年12月
52．本杰明，卢因编著，余龙江，松敏，赵寿元主译．基因Ⅷ．北京：科学出版社．2005年2月
53．周俊宜编著．分子生物学基本技能和策略．(21世纪高等院校教材)北京：科学出版社．2003年8月
54．张维铭主编．现代分子生物学实验手册．北京：科学出版社．2003年
55．曹亚主编，李官成副主编．实用分子生物学操作指南．北京：人民卫生出版社．2003年10月
56．刘进元等编著．分子生物学实验指导．北京：清华大学出版社．2002年
57．叶林柏，郜金荣编著．基础分子生物学．科学出版社．北京．2000年8月
58. Blumenthal RD, Leone E, Goldenberg. DM. Tumor-specific dose scheduling of bimodal radioimmunotherapy and chemotherapy. Anticancer Res, 2003, 23:4613-4619.
59．司徒镇强，吴军正主编．细胞培养，第一版，西安：世界图书出版社，2004年3月
60．卢红梅，强亦忠，施勤，等．p53基因状态对人卵巢癌细胞辐射敏感性的影响，辐射防护，2001，Vol．21(6)：205
61. Liu JR, Opipari AW, Tan L, et al.Dysfunctional apoptosome activation In ovarian cancer:implications for chemoresistance.Cancer Res, 2002.62:924-931
62．栾英姿，李力，黎丹戎，等．五种卵巢癌耐药细胞系的建立及其部分耐药相关基因的表达，中华妇产产科杂志，2006年6月39卷第6期403-408
63. Satoh T , Nishida M, Tsunoda H , et al . Expression of glutathione S-transferase pi (GST-pi) in human malignant ovariantumors. Eur J Obstet Gynecol Reprod Biol,2001,96 :202-208
64. Hill BT, Moran E, Etievant C, et al. Low-dose twice-daily fractionated X-irradiation of ovarian tumor cells in vitro generates drug-resistant cells overexpressing two multidrug resistance-associated proteins , P-glycoprotein and MRP1. Anticancer Drugs ,2000,11:193-200.
65. Cvitkovic E. Ongoing and unsaid on oxaliplatin : the hope.Br J Cancer ,1998 ,77 Suppl 4 :8-ll.
66. Perego P , Giarola M, Righetti SC , et al. Association between Cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996 ,56 :5562562.
67. Asselin E , Mills GB , Tsang BK. XIAP regulates Akt activity and caspase3-dependent cleavage durincisplatin-inducedapoptosis in human ovarian epithelial cancer cells. Cancer Res , 2001,61:1862-1868
68. Cui W, Yazlovitskaya EM, Mayo MS , et al . Cisplatin-induced responseof c-un N-terminal kinase and extracellularsignalregulated protein kinases 1 and 2 in a series Of cisplatin-resistant ovarian carcinoma cell lines.Mol Carcinog ,2000, 29 :219-228.
69. Mercer WE. Checking on the cell cycle [J] . J Cell Biochem Suppl ,1998,30 (31) :50-54.
70. Schwartz D , Rotter V. p532dependent cell cycle control : response to genotoxic stress[In Process Citation] [J] . Cancer Biol ,1998 ,8 (5) :325-336.
71. Sanding BV ,Brand K,Herwig S , et al . p16 and p53 genes transferred with the help of adenovirus to induce apoptic tumor cell death[J]. Ug-eskr Laeger, 1997, 159(46):6825-6830.
72. Xie K, Wang Y, Huang S, et al. Nitric oxide-mediated apoptosis of K-1735 melanoma cells is associated with downregulation of Bc122 [J].Oncogene, 1997, 15 (7):1923-1930.
73. Musat M, Vax W, Borboli N, et al. Cell cycle dysregulation in pituitary oncogenesis.Front Horm Res. 2004 ;32:34-62.
74. Ng SW, Yiu GK, Liu Y, et al.Analysis of p73 in human borderline and invasive ovarian tumor.Oncogene. 2000 Apr 6 ;19(15):1885-90.
75. Djelloul S. Tarunina M. Barnouin K. et al.Differential protein expression, DNA binding and interaction with SV40 large tumour antigen implicate the p63-family of proteins in replicative senescence Oncogene. 21(7):981-9, 2002 Feb 7.
76. Hagiwara K. McMenamin MG. Miura K.et al. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers Cancer Research. 59(17):4165-9, 1999 Sep 1.
77. Chen X. The p53 family: same response, different signals?. [Review] [64 refs] Molecular Medicine Today. 5(9):387-92, 1999 Sep.
78. Yang A. Kaghad M. Wang Y. et al.63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities Molecular Cell. 2(3):305-16, 1998 Sep
79. Yang A, Schweitzer R, Sun D. et al. p63 is essential for regenerative proliferation in limb, eraniofacial and epithelical developmentlJ]. Nature, 1999. 398(6729): 714-718.
80. Gwosdz C, Balz V, Scheckenbach K, Bier H.p53, p63 and p73 expression in squamous cell carcinomas of the head and neck and their response to Cisplatin exposure.Adv Otorhinolaryngol. 2005;62:58-71
81. Avivi A, Ashur-Fabian O, Amariglio N,et al.p53--a key player in tumoral and evolutionary adaptation: a lesson from the Israeli blind subterranean mole rat.Cell Cyc le. 2005 Mar;4(3):368-72. Epub 2005 Mar 11
82. Laurora S, Tamagno E, Briatore F,et al.4-Hydroxynonenal modulation of p53 family gene expression in the SK-N-BE neuroblastoma cell line.Free Radic Biol Med. 2005 Jan 15;38(2):215-25
83. Yu JJ. Bicher A. Ma YK.et al.The Tumor Suppressor Protein p53 Functions Similarly to p63 and p73 in Activating Transcription In Vitro.Cancer Biol Ther. 2005 Apr;4(4):414-8. Epub 2005 Apr 21
84. Flores ER, Sengupta S, Miller JB,et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family.Cancer Cell. 2005 Apr;7(4):363-73
85. Koutsodontis G, V.Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis.Biochem J. 2005 Jul 15;389(Pt 2):443-55
86.Kong CZ,Zhu YY,Ma ZY,et al.Expression of lung resistance-related protein gene in transitional cell carcinoma of the bladder]Zhonghua Wai Ke Za Zhi. 2005 Jan 15;43(2):118-21. Chinese..
87.Irwin MS. Family feud in chemosensitvity: p73 and mutant p53. [Review] [61 refs] Cell Cycle. 3(3):319-23, 2004 Mar.
88.Gressner O, Schilling T, Lorenz K, et al. TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO Journal. 24(13):2458-71, 2005 Jul 6.
89. Hirotaka N, Makoto S, Katsura HN, et al. p53 homologue p63 represses epidermal growth factor receptor expression [J]. J Biol Chem, 2001, 276(45):41717.
90. Luan YZ, Li L, Li DR, et al. Establishment of 5 resistant ovarian cancer cell strains and expression of resistance-related genes]. Journal of Obstetrics & Gynecology]. 39(6):403-7, 2004 Jun.
91. Coleman AB, Metz MZ, Donohue CA, et al.Chemosensitization by fibroblast growth factor-2 is not dependent upon proliferation, S-phase accumulation, or p53 status.BiochemicalPharmacology.64(7):1111-23, 2002 Oct 1.
1. Zeimet AG Marth C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncology. 2003 ,Jul. 4(7):415-22
2. Marzars GR ,Jeanteur P ,Lynch H T,et al. Nucleotide sequence polymorphism in a hotspot mutation region of the p53 gene[J] . Oncogene ,1992,7(4) :781 - 782.
3. Soussi TC ,de Fromental C, May P. Structural aspects of the p53 protein in relation to gene evlution[J]. Oncogene ,1990,5 :945 - 952.
4. Lamb P ,Crawford L. Characterization of the human p53 gene[J] . Mol Cell Biol ,1986 , 6 :1379 -1383.
5. Wamakulassuriya KA S S , Johson N N. Expression of p53 mutant nuclear phosphoprotein in oral carcinoma and potentially malignant oral lesions[J]. J Oral Pathol Med ,1992,21 :404 - 410.
6. Milner J ,Medcalf A. Co - translation of activated mutant p53 with wild type drives the wild type p53 protein into the mutant conformation[J] . Cell ,1991,65(5) :765 - 774.
7.Chen P L , Chen Y,Book stein R ,et al. Genetic mechanisms of tumor suppression by the human p53 gene[J]. Science ,1990,250 :1575 -1580.
8 . Holl stein M,Sidransky D ,Wagelstein B ,et al. p53 mutation in human cancer[J]. Science ,1991,253:49 - 55.
9. Cheng J ,Haas M. Frequent mutations in the p53 tumor suppressor gene in human Leukemia T- cell lines[J] . Mol Cell Biol ,1990 ,10(1) :5502 -5509.
10. Braithwaite A W,Sturzbecher H W,Addison C ,et al. Mouse p53 inhibits Sv40 origin-dependent DNA replication [J] . Nature ,1997 ,329(6137) :458 -460.
11. Raycroft L, Wu H, Lozano G. Transcriptional activation by wild-type but not transforming mutant of the p53 anti -oncogene[J] Science, 1997, 249:1049-1051.
12. Wang E H, Friedman D N, Privets C. The murine p53 protein blocks replication of SV40 in vitro by inhibiting the initiation functions of SV40 large T antigene[J]. Cell, 1989, 57:379-392.
13. Kern S E, Kinzler KW, Baker SJ, et al. Mutant p53 proteins bind DNA abnormally in vitro[J]. Oncogene, 1991, 6:131-136.
14. Kikuchi-Yanshita R, Konishi M, Fukunari H, et al. Loss of expression of the DCC gene during progression of colorectal carcinomas in familial adenomatous polyposis and non-familial adenomatous [J]. Cancer Res, 1992, 52(12):3801-3803.
15. Gannon J V, Lane D P. p53 and DNA polymerase a completed for binding to SV40Tantigen[J] Ntaure 1987 ;329:456-458.
16. Hunter T York JD. Signal transduction. Unexpected mediators of protein phosphorylation.[comment], Science. 2004 Dec 17 ;306(5704):2101-5 ;
17. Mercer WE. Checking on the cell cycle. [Review] [25 refs] Journal of Cellular Biochemistry-Supplement. 1998. 30-31:50-4,
18. Schwartz D. Rotter V. p53-dependent cell cycle control: response to genotoxic stress. [Review] [172 refs] Seminars in Cancer Biology. 1998. 8(5):325-36,
19. Sandig BV. Brand K. Herwig S. Lukas J. Bartek J. Strauss M. [p16 and p53 genes transferred with the help of adenovirus to induce apoptic tumor cell death]. [Danish] Ugeskrifl for Laeger. 1997 Nov 10. 159(46):6825-30
20. Buckbinder L. Velasco-Miguel S. Chen Y. Xu N. Talbott R. Gelbert L. Gao J. Seizinger BR. Gutkind JS. Kley N. The p53 tumor suppressor targets a novel regulator of G protein signaling.Proceedings of the National Academy of Sciences of the United States of America. 1997 Jul 94(15):7868-72
21. Wang Y. Blandino G. Oren M. Givol D. Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs.Oncogene. 1998 Oct 15. 17(15):1923-30
22. Lonardo F. Ueda T. Huvos AG. Healey J. Ladanyi M. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Cancer. 79(8):1541-7, 1997 Apr 15.
23. Ling-Ling, Hsieh ;Jen-Tsung, Hsieh ;LI-Yu, Wang ;Chiung-Yau, Fang ;Shan-Hong, Chang ;Tse-Ching, Chen.P53 mutations in gastric cancer from Taiwan.Cancer Letters.volume:100, Issue:1-2, February 27, 1996 ; 107-113
24. Wang, Jaw-Yuan: Hsieh, Jan- en-Lu ;Chen, Fang-Ming ;et al.Alterations of APC, c-met, and P53genes in tumor tissue and serum of patients with gastric cancers.Journal of Surgical Research.Volume:120, Issue:2, August, 2004, pp.242-248
25. Mineta H. Miura K. Ogino T. Takebayashi S. Misawa K. Ueda Y. Vascular endothelial growth factor (VEGF) expression correlates withp53 and ki-67 expressions in tongue squamous cell carcinoma. Anticancer Research.22(2B): 2002 Mar-Apr. 1039-44,
26. wabuchi S. Muramatsu H. Chiba N. Kinio Y. Murakami Y. Sakaguchi T. Yokoyama K. Tamiya E. Simultaneous detection of near-field topographic and fluorescence images of human chromosomes via scanningnear-fieldoptical/atomic-force microscopy (SNOAM). Nucleic Acids Research.,1997 Apr 15. 25(8): 1662-3,
27. Nakai H. Misawa S. Toguchida J. Yandell DW. Ishizaki K. Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. Cancer Research. 52(23):6588-93,1992 Dec 1.
28. Wagata T,Shibagaki I , Imamurna M,et al. Loss of 17p ,mutation of the p53 gene , and overexpression of protein in esphageal seqamous cell carcinomas[J]. Cancer Res ,1993 ,53 :846 - 850.
29. Green M R. When the products of oncogenes and antioncogenes meet [J]. Cell ,1989 ,56:1-5.
30. Wolf D ,Harris N , Rotter V. Reconstitution of p53 expression in a nonproducer Ab - MulV - transformed cell line by transinfection of a functional p53 gene[J]. Cell ,1984,38 :119 -126.
31. Seruca R ,David L ,Holm R ,et al. p53 mutations in gastric carcinomas[J]. Br J Cancer ,1992 ,65(5) :708 - 710.
32.Sprunck C ,Tsai Y C ,Huang D P ,et al. Absence of p53 gene mutation in primarynasopharyngealcarcinomas[J] .Cancer Res ,1992 ,52(16) :4787 -4790.
33 Saramath D ,Panchnal R G,Nair R ,et al. Oncogene amplification in squamous cell of the oral cavity[J] . Jpn J Cancer Res ,1989 ,80 :430 - 434.
34. Maestro R, Dolcett R, Gasparotto D, et al. High frequency of p53 gene alte human squamous cell carcinoma of the larynx[J]. Oncogene, 1992, 7:1157-1166.
35．周向东，沈寒放，谭骏．p53基因缺失和248位密码子点突变与肺癌发生和预后间关系的研究[J]．中国肿瘤临床997，24(6)：415-418．
36．余春艳，魏峰，顾群，等．外阴白斑和鳞癌细胞中p53蛋白的表达[J]．第四军医大学学报，2000，21(4)：462-463．
37. Yuan Y, Kim W H, Han H S, et al. Establishment and characterization of humanovarian carcinoma cell lines[J]. Gynecol Oncol, 1997, 66(3):378-387.
38. Rodrigues N R, Rowan A, Smith M E F, et al. p53 mutation in colorectal cancer [J]. Proc Natl Acad Sci USA, 1990, 87:7555-7559.
39. Luria D, Avgad S, Cohem I J, et al. p53 mutation as the second event in juvenile chronic myelogenous leukemia in a patient with neurofibromatosis type Ⅰ[J]. Cancer, 1997, 80(10):2013-2018.
40. Cherney B W, Bhatia K G, Sgadavi C, et al. Role of the p53 tumor suppressor gene in the tumorigenicity of Burkittps lymphoma cells[J]. Cancer Res, 1997, 57(12):2508-2515.
41．张晓东，王文亮，穆峰．肝癌细胞转染野生型p53基因稳定表达后肝癌细胞出现自发凋亡[J]．第四军医大学学报，1996，17(6)：469-470．
42．郭洪涛，刘彤华，高洁．人胰腺癌中MDM2癌基因的表达对野生型p53的拮抗作用[J]．中华病理学杂志，1996，25(4)：232-235．
43．张玉玲．腺病毒介导的野生型p53表达诱导前列腺癌细胞死亡并抑制肿瘤形成[J]．国外医学(分子生物学分册，1996，18(5)：239．
44．李东霞，涂平，马圣清．皮肤鳞状上皮细胞肿瘤p53蛋白的表达[J]．中华皮肤科杂志，1996，29(1)：41-42．
45. Nigro J M, Baker S J, Presinger A C, et al. Mutations in the p53 gene occur in diverse human types[J]. Nature, 1989, 342:705-708.
46. Shimada T. Current status and future prospects of human gene therapy. [Review] [27 refs] Acta Paediatrica Japonica. 1996 Apr. 38(2):176-81
47. Chen Xiaowei ; Cao Keli ; Liu Depei ; Wang Zhizhong ; Liang Chihchuan. Construction of the wt-p53 Gene Recombinant Retroviral Vector Inhibiting the Growth of Laryngocarcinoma Cell Line.ACTA ACADEMIAE MEDICINAE SINICAE.1996(4):179-181
47. Cascallo M. Capella G. Mazo A. Alemany R. Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Research. 2003 Sep 1. 63(17):5544-50
48. Blasco F. Penuelas S. Cascallo M. Hernandez JL. Alemany C. Masa M. Calbo J. Soler M. Nicolas M. Perez-Torras S. Gomez A. Tarrason G. Noe V. Mazo A. Ciudad CJ. Piulats J. Expression profiles of a human pancreatic cancer cell line upon induction of apoptosis search for modulators in cancer therapy. Oncology. 2004. 67(3-4):277-90
49. Chin KV. Alabanza L. Fujii K. Kudoh K. Kita T. Kikuchi Y Selvanayagam ZE. Wong YF. Lin Y. Shih WC. Application of expression genomics for predicting treatment response in cancer. Annals of the New York Academy of Sciences. 2005 Nov. 1058:186-95,
50. Thottassery JV. Westbrook L. Someya H. Parker WB. c-Abl-independent p73 stabilization during gemcitabine-4'-thio-beta-D-arabin of uranosy lcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells.Molecular Cancer Therapeutics. 2006 Feb. 5(2):400-10,
51. Li JH. Lax SA. Kim J. Klamut H. Liu FF. The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma. International Journal of Radiation Oncology, Biology, Physics. 1999 Feb 1. 43(3):607-16,
52. Popham HJ. Bischoff DS. Slavicek JM. Both Lymantria dispar nucleopolyhedrovirus enhancin genes contribute to viral potency. Journal of Virology. 2001 Sep. 75(18):8639-48,
53.Lee,Chien-Hsin;Ni,Yen-Hsuan;Chen,Chia-Chi;Chou,Chen-Kung;Chang,F u-Hsiung.Synergistic effect of polyethylenimine and cationic liposomes in nucleic acid delivery to human cancer cells.Biochimica et Biophysica Acta(BBA)/Biomembranes, Volume: 1611, Issue: 1-2, April 1, 2003, pp. 55-62
54.Skilling Jeffiey S; Squatrito, Robert C; Connor, Joseph P;, Niemann, Theodore; Buller Richard E p53 Gene Mutation Analysis and Antisense-Mediated Growth Inhibition of Human Ovarian Carcinoma Cell Lines Gynecologic Oncology Volume: 60, Issue: 1, January, 1996, pp. 72-80
55. Buller RE. Sood AK. Lallas T. Buekers T. Skilling JS. Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer.[see comment]. Journal of the National Cancer Institute. 1999 Feb 17. 91(4):339-46
56. Bishop MR. Iversen PL. Bayever E. Sharp JG. Greiner TC. Copple BL. Ruddon R. Zon G. Spinolo J. Arneson M. Armitage JO. Kessinger A. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. [see comment]. Journal of Clinical Oncology. 1996 Apr. 14(4): 1320-6
57 .Gomyo Y. Sasaki J. Branch C. Roth JA. Mukhopadhyay 5-aza-2'-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells. Oncogene. 2004 Sep. 23(40):6779-87,
58. Yanuck M. Carbone DP. Pendleton CD. Tsukui T. Winter SF. Minna JD. Berzofsky JA. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Research. 1993 Jul 53(14):3257-61
59. Ciernik IF. Berzofsky JA. Carbone DP. Human lung cancer cells endogenously expressing mutant p53 process and present the mutant epitope and are lysed by mutant-specific cytotoxic T lymphocytes.Clinical Cancer Research. 1996 May. 2(5):877-82,
60. Wilson JM. Gendicine: the first commercial gene therapy product. [Chinese, English] Human Gene Therapy. 16(9): 1014-5, 2005 Sep.
61. Patil SD. Rhodes DG. Burgess DJ. DNA-based therapeutics and DNA delivery systems: a comprehensive review. [Review] [159 refs] AAPS Journal., 2005. 7(1):E61-77
62. Kaghad M,Bonner H, Yang A,etal.Monoallelically expressed gene related to P53 at P63,a region frequently deleted in neuroblastoma and other human cancers[J].Cell. 1997,90(4):809.
63. Yang A,Kaghad M, Wang Y,et al.P63,a p53 homolog at 3q27-29,encodes multiple productswith transactivating,death-inducing, and dominant-negative activities[J].Mol cell.1998,2(3):305
64. Schmale H , Bamberger C. A novel protein with strong homology to the tumor suppressor p53 [J]. Oncogene , 1997 ,15 (11) :1363.
65. Osada M , Ohba M , Kawahara C , et al. Cloning and func2 tional analysis of human p51 , which structurally and func2tionally resembles p53[J]. Nat. Med , 1998 ,4(7) :839.
66. Trink B , Okami K, Wu L , et al. A new human p53 homo2 logue[J] . Nat. Med, 1998,4(7) :747.
67. Senoo M , Seki N, Ohira M , et al. A second p532related protein , p73L, with high homology to p73 [J] . Biochem Biophys Res Commun , 1998,248(3) :603.
68. Tan M , Bian J , Guan K, et al. p53CP is p51/ p63 , the third member of the p53 gene family : partial purification and characterization[J] . Carcinogenesis , 2001,22(2) :295.
69. Lee L , Walsh P , Prater C , et al. Characterization of an au2 toantigen associated with chronic ulcerative stomatitis : TheCUSP autoantigen is a member of the p53 family[J]. J In2 vest Dermatol, 1999,113(2) .146.
70. Zeng X, Zhu Y, Lu H. NBP is the p53 homolog p63[J] .Carcinogenesis, 2001,22(2) : 215.
71. Ratovitski EA , Patturajan M , Hibi K, et al. p53 associates with and targets Delta Np63 into a protein degradation vitski EA,Patturajan M,Hibi K,et al.P53 associates with and targets Delta Np63 into a protein degradation pathway[J].Proc Natl Acad Sci USA,2001,98(4):1817
72. Irwin MS, Kaelim WG. p53 familv update: p73 and p63develop their own identities[J]. Cell Growth Differ, 20012(7): 337—349.
73. Benard J, Douc-Rasy S, Ahomadegbe JC. TP53 family members and human cancers[J]. Hum Mutat. 2003, 21(3): 182-191
74.VogelsteinB,LaneD,LevineAJ.SurfingtheP53net-work.[J]Nature,2000.408 (6810):307
75. Yang A, Schweitzer R, Sun D. et al. p63 is essential for regenerative proliferation in limb , eraniofacial and epithelical development[J]. Nature, 1999. 398(6729): 714—718
76. Irwin MS, Kaelim WG. p53 family update: p73 and p63 develop their ownidentities[J]. Cell Growth Differ, 2004.12(7): 337—349.
77. Yang A , Kaghad M , Wang Y, et al. p63 , a p53 homolog at 3q27-29 , encodes multiple products with transactivating ,death-inducing , and dominant-negative activities [J]. Mol Cell, 1998,2(3) :305.
78. Schmale H , Bamberger C. A novel protein with strong homology to the tumor suppressor p53 [J]. Oncogene, 1997 ,15 (11) :1363.
79. Osada M , Ohba M , Kawahara C , et al. Cloning and functional analysis of human p51 , which structurally and functionally resembles p53[J] . Nat. Med, 1998 ,4(7) :839.
80. Trink B , Okami K, Wu L, et al. A new human p53 homologue[J]. Nat. Med, 1998 ,4(7) :747.
81. Senoo M , Seki N , Ohira M , et al. A second p53-related protein , p73L, with high homology to p73 [J] . Biochem Biophys Res Commun , 1998 ,248(3) :603.
82 .Parsa R , Yang A , McKeon F , et al. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes [J]. J Investig Dermatol, 1999 ,113 (6) :
83. Quade BJ , Yang A , Wang Y, et al. Expression of the p53 homologue p63 in early cervical neoplasia[J]. Gynecol. Oncol, 2001,80 (1) :24.
84. Senoo M , Matsumura Y, Habus S , et al. Tap63gamma(p51A) and dNp63aipha (p73L), two major isoforms of the p63 gene , exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression [J]. Oncogene ,2002,21 (16) :2455.
85. Hirotaka N, Makoto S , Katsura HN , et al. p53 homologue p63 represses epidermal growth factor receptor expression [J]. J Biol Chem, 2001,276(45) :41717.
86. Vincek V,Knowles N,Ii J.et al.Expression of P63mRNA isoforms in normal human tissue(J).Anticancer Res,2003.23(5A):3945-3948.
87. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes muhipie products with transactivatin death·inducing, and dominant negative activities [J]. Mol Cell,1998,2(3):305
88. Tsujita-kyutoku M,Kiuchi K,Danbara N,et al.P63 espression in normal human epidermjis and epidermal appendageas and their tumors(J).Jeutan Pathol,2003,30(1):11-17
89. Van Bokhoven H ,Brunner HG. Splitting p63 [J] . Am J Hum Genet ,2002,71 (1) :1213.
90. Westfall MD ,Pietenpol J p63 :Molecular complexity in development and cancer[J]Carcinogenesis ,2004,25(6) :8572864.
91. Strano E ,Munarriz H. Physical interaction with Yes - associated pro2 tein enhances p73 transcriptional activity [J]. Biol Chem,2001,276 : 15164 -15173.
92 .Chi SW,Ayed A. Solution structure of a conserved C - terminal domin of p73 with structural homology to the SAM domain[J]. EMBO ,1999 , 18 :4438 - 4445.. Carcinogenesis ,2004 ,25(6) :8572864.
93. Mills AA , Zheng B , Wang XJ , et al. p63 is a p53 homologue required for limb and epidermal morphogenesis [J] .Nature , 1999,398(6729): 708.
94. Yang A , Schweitzer R , Sun D , et al. p63 is essential for regenerativproliferatio in limb , craniofacial and epithelial development [J]. Nature , 1999 ,398(6729) :714.
95. Celli J , Duijf P , Hamel BCJ , et al. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome[J] . Cell , 1999,99(2): 143.
96. Ianakiev P , Kilpatrick MW , Toudiarsk I ,et al Split-hand/split-foodmal formation is caused by mutations in the p63 gene on 3q27[J] Am J Hum Genet ,2000 ,67(1) :59.
97. McGrath JA , Duijf PH , Doetsch V , et al. Hay-Wells syndrome is caused by het2001,10 (3) :221.
98. Chompret A. The Li-Fraumeni syndrome [J] . Biochimie.erozygous missense mutations in the SAM domain of p63 [J] . Hum Mol Genet, ,2002 84 (1) :75
99. Park BJ , Lee SJ , Kim J I, et al. Frequent alteration of p63 expression in human primary bladder carcinomas[J]. Cancer Res , 2000,60(13) :3370.
100. Sunahara M , Shishikura T , Takahashi M , et al. Mutational analysis of p51A/ TAp63gamma , a p53 homolog , in non small cell lung cancer and breast cancer [J]. Oncogene ,1999 ,18 (25) :3761.
101. Hibi K, Trink B , Patturajan M , et al. AIS is an oncogene amplified in squamous cell carcinoma[J] . Proc Natl Acad Sci USA , 2000,97(10) :5462.
102. Liefer KM , Koster MI , Wang XJ , et al. Down-regulation of p63 is required for epidermal UV2B2induced apoptosis[J] .Cancer Res , 2000 ,60(15) :4016.
103. Mai M , Huang H , Reed C , et al. Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p2arm deletions [J].Genomics ,1998, 51(3) :359.
104. Marin MC , Kaelin W. p63 and p73 : old members of a new family[J] .Biochem BiophysActa, 2000,1470(3) :93.
105. Osada M,Ohba M,Kawabara C, et al. Cloning and functional analysis of human p51 ,which structurally and functionally resembles p53 [J]. Nat Med ,1998,4 (7) .839-843.
106. Di Como CJ ,Urist MJ ,Babayan I , et al . p63 expression profiles in human normal and tumor tissues[J] . Clin Cancer Res ,2002 ,8 (2) :494-501.
107. Reis-Filho JS ,Simpson PT ,Martins A , et al . Distributionofp63 ,cytokeratins 5/ 6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP24 multi-tumor tissue microarray [J]. Virchows Arch ,2003 ,443(2) :122-132.
108. Massion PP ,Taflan PM,Jamshedur Rahman SM, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis[J]. Cancer Res ,2003 ,63(21) :7113-7121.
109. Chen YK,Huse SS ,Lin LM, et al. Differential expression of p53 ,p63 and p73 proteins in human buccal squamous2cell carcinomas[J]. Clin Otolaryngol ,2003 ,28(5) :451-455.
110. Qureshi HS ,Ormsby AH ,Lee MW, et al. The diagnostic utility of p63 , CK5/ 6 ,CK7 ,and CK 20 in distinguishing primary cutaneous adnexal neoplasms from metastatic carcinomas [J] . J Cutan Pathol , 2004 , 31(2):145-152.
111. Park BJ ,Lee SJ ,KimJ I, et al. Frequent alteration of p63 expression in human primary bladder carcinomas [J] . Cancer Res ,2000 , 60 (13) :3370-3374.
112. Langner C, Ratschek M, Tsybrovskyy O, et al. p63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal cell carcinoma even in poorly differentiated tumors [J] .Histochem Cytochem,2003 ,51(8): 1097-1099.
113. Reis-Filho JS ,Milanezi F ,Amendoeira I, et al. Distribution of p63 ,a novel myoepithelial marker , in fine-needle aspiration biopsies of the breast: an analysis of 82 samples[J]. Cancer ,2003 ,99 (3) .172-179.
114. Stefanou D ,Batistatou A ,Nonni A, et al. p63 expression in benign and malignant breast lesions[J]. Histol Histopathol ,2004 ,19(2) :465-471.
115. Unger P ,Ewart M,Wang BY, et al . Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis : a pathobiologic link[J] ?Hum Pathol ,2003 ,34(8) .764-769.
116. Mai M , Huang H , Reed C , et al. Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions [J]. Genomics , 1998 , 51(3) :359.
117. Kaghad M , Bonnet H , Yang A , et al. Monoallelically expressed gene related to p53 at 1p36 , a region frequently deleted in neuroblastoma and other human cancers[J] . Cell. 1997 , 90 (4) :809.
118. Marin MC , Kaelin W. p63 and p73 : old members of a new family[J] .Biochem BiophysActa, 2000,1470(3) :93.
119. Arrowsmith CH. Structure and function in the p53 family [J] . Cell Death Differ, 1999 ,6(12) :1169.
120. Kaghad M, Bonnet H , Yang A , et all Monoallelically expressed gene-related to P53 at 1p36 , a region frequently deleted in neuroblastoma and other human cancer[J]1 Cell ,1997,90(4) :809 - 819
121. Chi SW, Ayed A , Arrowsmith CH1 Solution structure of a conserved C-terminaldomain of P73 withstructura lhomology to the SAM domain [J] EMBOJ ,1999 ,18(16) :4438 - 4445
122. Yang A , Kaghad M, Wang Y, et all P63 ,a P53 homolog at 3q27-29 ,encodes multiple products with transactivating death-inducing and dominant negative activities[J]MoI Cell ,1998,2 (3) :305 - 316
123. Nakagawa T , Takahashi M, Ozaki T , et all Autoinhibitory regulation of P63 byANP73 to modulate cell survival and death through a P732specific target element within theANP73 promoter[J]lMol Cell Biol ,2002 ,22(8) :2575 - 2585
124. Kartasheva N, Contente A, Lenz2St¨oppler C, et all P53 induces the expression P73AN , establishing an autoregulatory feedback loop [J]Oncogene , 2002 ,21(31): 4715 - 4727
125. Haupt Y, Maya R , Kazaz A , Oren M1MDM2 promotes the rapid degradation of P53[J],Nature ,1997 ,387 (6630) :296 - 299
126. Minty A, Dumont X, Kaghad M, et all Cvalent modification of P73a by SUMO211Two2hybrid screening with P73 identifies novel SUMO21 in-teracting proteins and a SUM021 interaction motif [J] 1J Boil Chem,2000,275 (46) :36316 - 36323
127. Calabro V , Mansueto G, Parisi T, et all The human MDM2 oncopro tein increases the transcriptional activity and the protein level of the P53-homologue P63[J]1J Biol Chem,2001,277(4) :2674 - 2681
128. Stiewe T, Theseling CC, Putzer BM1 Transactivation deficient Delta TaP73 inhibits P53 by direct competition for DNA binding implications for tumorigenesis[J]J Biol Chem,2002,277(16): 14177 -14185
129. Grob TJ , FeyMF, Tobler A1 The two faces of P73[J]1Cell Death Dif feer, 2002,9(3) :237-245
130. Irwin Ms, Kaelin WG1P53 family update : P73 and P63 develop their own identities[J]1 Cell Growth Differ ,2001,12(7) :337 - 349
131. Kaghad M, Bonnet H, Yang A, et all Monoallelically expressed gene related to P53 at 1p36 , a region frequently deleted in neuroblastoma and other human cancer[J]1 Cell ,1997,90(4) :809 - 819
132. Yang A , Kaghad M, Wang Y, et all P63 ,a P53 homolog at 3q27-29 ,encodes multiple products with transactivating death-inducing and dominant negative activities[J]Mol Cell ,1998,2 (3) :305 - 316
133. Ozaki T , Nala M, Takda N , et all Deletion of the COOH-terminal region of P73alpha enhances both its transactivation function and DNA binding activity but inhibits induction of apoptosis in mammalian cells [J] Cancer Res , 1999 , 59 (23): 5902 - 5907
134. Gong J , Costanzo A , Yang H , et all The tyrosine kinase c-Abl regulates P73 in apoptotic response to cisplatin-induced DNA damage [J]Nature, 1999, 399(6738): 806-808
135. Liefer KM, Koster MI, Wang XJ, et all Down-regulation of P63 is require for epidermal UVB-induced apoptosis [J] Cancer Res, 2000, 60(15):4016-4020
136. Flores ER, Tsai KY, Crowley D, et all P63 and P73 are required for P53-dependent apoptosis in response to DNA damage[J] Nature, 2002, 416(6880): 560-564
137. Strano S, Fontemaggi G, Costanzo A, et all Physical interaction with human tumor-derived P53 mutants inhibits P63 activities [J] JBiolChem, 2002, 277(21):8817-1882
138. Park JJ, Sun D, Quade BJ, et all Stratified mucin-producing intraepithelial lesions of the cervix: adenosquamous or columnar cell neoplasia[J]AmJ Surg Pathol, 2000, 24(10):1414-1419
139. Patturajan M, Nomoto S, Sommer M, et all ΔNP63 induces β-catenin nuclear accumulation and signaling [J] Cancer Cell, 2002, 1(4):369-379
140. Yang A, Schweitzer R, Sun D, et all P63 is essential forregenerativeproliferation in limb, craniofacial and epithelial development [J]Nature, 1999, 398 (6729):714-718
141. Celli J, Duijf P, Hamel BC, et all Heteozygous gremlin mutations in the P53 homolog P63 are the cause of EEC syndrome[J]1 Cell, 1999, 99(2):143-153
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |